Search

Your search keyword '"Mahadevan, Daruka"' showing total 701 results
Start Over Author "Mahadevan, Daruka"
701 results on '"Mahadevan, Daruka"'

1. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Author

Bullock, Andrea J., Schlechter, Benjamin L., Fakih, Marwan G., Tsimberidou, Apostolia M., Grossman, Joseph E., Gordon, Michael S., Wilky, Breelyn A., Pimentel, Agustin, Mahadevan, Daruka, Balmanoukian, Ani S., Sanborn, Rachel E., Schwartz, Gary K., Abou-Alfa, Ghassan K., Segal, Neil H., Bockorny, Bruno, Moser, Justin C., Sharma, Sunil, Patel, Jaymin M., Wu, Wei, Chand, Dhan, Rosenthal, Katherine, Mednick, Gabriel, Delepine, Chloe, Curiel, Tyler J., Stebbing, Justin, Lenz, Heinz-Josef, O’Day, Steven J., and El-Khoueiry, Anthony B.

Published
2024
Full Text
View/download PDF

2. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).

Author

Babiker, Hani, Borazanci, Erkut, Subbiah, Vivek, Agarwala, Sanjiv, Algazi, Alain, Schachter, Jacob, Lotem, Michael, Maurice-Dror, Corinne, Hendler, Daniel, Rahimian, Shah, Minderman, Hans, Haymaker, Cara, Mahadevan, Daruka, Bernatchez, Chantale, Murthy, Ravi, Hultsch, Rolf, Kaplan, Nadia, Woodhead, Gregory, Hennemeyer, Charles, Chunduru, Srinivas, Anderson, Peter, Diab, Adi, and Puzanov, Igor

Subjects
Humans, Toll-Like Receptor 9, Antigen Presentation, Neoplasms, Melanoma, Cohort Studies, Skin Neoplasms, Tumor Microenvironment
Abstract

PURPOSE: Tilsotolimod is an investigational synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. The ILLUMINATE-101 phase I study explored the safety, dose, efficacy, and immune effects of intratumoral (it) tilsotolimod monotherapy in multiple solid tumors. PATIENTS AND METHODS: Patients with a diagnosis of refractory cancer not amenable to curative therapies received tilsotolimod in doses escalating from 8 to 32 mg into a single lesion at weeks 1, 2, 3, 5, 8, and 11. Additional patients with advanced malignant melanoma were enrolled into an expansion cohort at the 8 mg dose. Objectives included characterizing the safety, establishing the dose, efficacy, and immunologic assessment. Blood samples and tumor biopsies of injected and noninjected lesions were obtained at baseline and 24 hours after treatment for immune analyses. RESULTS: Thirty-eight and 16 patients were enrolled into the dose escalation and melanoma expansion cohorts, respectively. Deep visceral injections were conducted in 91% of patients. No dose-limiting toxicities (DLT) or grade 4 treatment-related adverse events were observed. Biopsies 24 hours after treatment demonstrated an increased IFN pathway signature and dendritic cell maturation. Immunologic profiling revealed upregulation of IFN-signaling genes and modulation of genes for checkpoint proteins. In the dose escalation cohort, 12 (34%) of 35 evaluable patients achieved a best overall response rate (ORR) of stable disease (SD), whereas 3 (19%) of 16 evaluable patients in the melanoma cohort achieved stable disease. CONCLUSIONS: Overall, tilsotolimod monotherapy was generally well tolerated and induced rapid, robust alterations in the tumor microenvironment. See related commentary by Punekar and Weber, p. 5007.

Published
2022

4. Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical research

Author

Vidal, Gregory A., Chalela, Patricia, Curry, Andrea N., El-Rayes, Bassel, Halmos, Balazs, Herrera, Alex F., Kapoor, Kapil G., Kaur, Supreet, Mahadevan, Daruka, Mesa, Ruben, Ramirez, Amelie, Sleckman, Barry, Wagner, Alan L., Bhagat, Ruma, Brown, Isabel, Cruz, Leia, Funwie, Audrey, Highsmith, Quita, Richie, Nicole, and McKenzie, Meghan

Published
2024
Full Text
View/download PDF

5. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Author

Fong, Lawrence, Hotson, Andrew, Powderly, John D, Sznol, Mario, Heist, Rebecca S, Choueiri, Toni K, George, Saby, Hughes, Brett GM, Hellmann, Matthew D, Shepard, Dale R, Rini, Brian I, Kummar, Shivaani, Weise, Amy M, Riese, Matthew J, Markman, Ben, Emens, Leisha A, Mahadevan, Daruka, Luke, Jason J, Laport, Ginna, Brody, Joshua D, Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W, Berim, Lyudmyla, Renouf, Daniel J, Goodwin, Rachel A, Munneke, Brian, Ho, Po Y, Hsieh, Jessica, McCaffery, Ian, Kwei, Long, Willingham, Stephen B, and Miller, Richard A

Subjects
Kidney Disease, Rare Diseases, Immunization, Cancer, Vaccine Related, Biotechnology, Clinical Research, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Aetiology, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Furans, Humans, Kidney Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Pyridines, Pyrimidines, Receptor, Adenosine A2A, Salvage Therapy, Survival Rate, Oncology and Carcinogenesis
Abstract

Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling in vivo. In a cohort of 68 patients with renal cell cancer (RCC), we also observe clinical responses alone and in combination with an anti-PD-L1 antibody, including subjects who had progressed on PD-1/PD-L1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8+ T cells into the tumor. Treatment can also broaden the circulating T-cell repertoire. Clinical responses are associated with an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-1/PD-L1 that restricts antitumor immunity. SIGNIFICANCE: This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent and anti-PD-L1 combination therapy in patients with refractory RCC. Responding patients possess an adenosine-regulated gene-expression signature in pretreatment tumor biopsies.See related commentary by Sitkovsky, p. 16.This article is highlighted in the In This Issue feature, p. 1.

Published
2020

7. A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma.

Author

Subramani, Baskaran, Conway, Patrick J., Al-Khinji, Aisha, Zhang, Kun, Pandey, Ritu, and Mahadevan, Daruka

Abstract

Simple Summary: The mantle cell lymphoma field has advanced significantly due to ongoing developments in molecular pathogenesis prediction and novel therapeutic approaches. The area has undergone a revolution with the development of Bruton tyrosine kinase inhibitors, which are now the cornerstone of R/R MCL therapy. Developing and implementing new targeted and combination approaches has already improved therapeutic options, especially for refractory or relapsed diseases. Background/Objectives: Aurora (AK) A/B are oncogenic mitotic kinases that when over-expressed are poor prognostic markers in mantle cell lymphoma (MCL). Methods and Results: Alisertib, an AK-A inhibitor, has anti-tumor activity in relapsed/refractory (r/r) MCL patients. We evaluated alisertib plus ibrutinib in MCL to abrogate ibrutinib resistance. Alisertib plus ibrutinib was therapeutically synergistic on both Granta-519 insensitive to ibrutinib and JeKo-1 cells sensitive to ibrutinib. Alisertib decreased PI-3K, BTK, p38, HCK, and RSK kinases, indicative of its multipotent effect on cellular proliferation and growth. A mouse xenograft model of Granta-519 demonstrated that alisertib plus ibrutinib had a comparable anti-tumor response to ibrutinib plus rituximab. However, alisertib plus ibrutinib plus rituximab demonstrated significantly stronger tumor growth inhibition than the doublets. Conclusions: Both double and triple combinations showed enhanced survival versus ibrutinib alone. Ibrutinib insensitivity can be disrupted by alisertib plus ibrutinib in MCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Author

Gregory, Gareth P., Kumar, Shaji, Wang, Ding, Mahadevan, Daruka, Walker, Patricia, Wagner-Johnston, Nina, Escobar, Carolina, Bannerji, Rajat, Bhutani, Divaya, Chang, Julie, Hernandez-Ilizaliturri, Francisco J., Klein, Andreas, Pagel, John M., Rybka, Witold, Yee, Andrew J., Mohrbacher, Anne, Huang, Mo, Farooqui, Mohammed, Marinello, Patricia, and Quach, Hang

Published
2022
Full Text
View/download PDF

10. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

Author

Carducci, Michael, Shaheen, Montaser, Markman, Ben, Hurvitz, Sara, Mahadevan, Daruka, Kotasek, Dusan, Goodman, Oscar B, Rasmussen, Erik, Chow, Vincent, Juan, Gloria, Friberg, Gregory R, Gamelin, Erick, Vogl, Florian D, and Desai, Jayesh

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Administration, Oral, Adult, Aged, Aurora Kinases, Biomarkers, Tumor, Cohort Studies, Dose-Response Relationship, Drug, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Neoplasms, Phthalazines, Progression-Free Survival, Protein Kinase Inhibitors, Treatment Outcome, AMG 900, Antimitotic, Aurora kinase, pan-Aurora kinase inhibitor, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Pharmacology and pharmaceutical sciences
Abstract

Background Aurora kinase overexpression or amplifications are associated with high proliferation, poor prognosis, and therapeutic resistance in human tumors. AMG 900 is an investigational, oral, selective pan-Aurora kinase inhibitor. Methods This first-in-human trial included dose-escalation and dose-expansion phases ( ClinicalTrials.gov : NCT00858377). Dose escalation evaluated the safety, tolerability, and pharmacokinetics of AMG 900 in advanced solid tumors and determined the maximum tolerated dose (MTD) with/without granulocyte colony-stimulating factor (G-CSF) prophylaxis. Dose expansion evaluated clinical activity in three tumor types: taxane- and platinum-resistant ovarian cancer, taxane-resistant triple-negative breast cancer (TNBC), and castration-resistant and taxane- or cisplatin/etoposide-resistant prostate cancer (CRPC). AMG 900 was administered 4 days on/10 days off at 1-50 mg/day during escalation and at the MTD with G-CSF during expansion. Results AMG 900 showed rapid absorption with fast clearance, supporting once-daily dosing. The MTD was 25 mg/day, increasing to 40 mg/day with G-CSF. Grade ≥ 3 treatment-related adverse events included neutropenia (37%), anemia (23%), leukopenia (14%), and thrombocytopenia (12%). During dose expansion, 3/29 (10.3%, 95% CI: 2.0%-28.0%) evaluable patients with ovarian cancer experienced partial response by central imaging per RECIST 1.1; median duration of response was 24.1 weeks (95% CI: 16.1-34.1). Seven patients (24.1%, 95% CI: 10.3%-43.5%) experienced partial response per Gynecologic Cancer InterGroup criteria; 5/9 patients positive for p53 expression responded to treatment. No objective responses were observed in patients with TNBC or CRPC per RECIST 1.1. Conclusions AMG 900 40 mg/day with G-CSF had manageable toxicity and demonstrated single-agent activity in patients with heavily pretreated, chemotherapy-resistant ovarian cancer.

Published
2018

11. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Author

Kim, Edward S, Kelly, Karen, Paz-Ares, Luis G, Garrido, Pilar, Jalal, Shadia, Mahadevan, Daruka, Gutierrez, Martin, Provencio, Mariano, Schaefer, Eric, Shaheen, Monte, Johnston, Erica L, Turner, P Kellie, Kambhampati, Siva Rama Prasad, Beckmann, Richard, Hossain, Anwar, John, William J, and Goldman, Jonathan W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Lung, Clinical Trials and Supportive Activities, Digestive Diseases, Cancer, Lung Cancer, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Female, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non-small cell lung cancer (NSCLC). A multicenter, nonrandomized, open-label phase Ib study was conducted to test safety, MTD, pharmacokinetics, and preliminary antitumor activity of abemaciclib in combination with other therapies for treatment in patients with metastatic NSCLC.Patients and Methods: An initial dose escalation phase was used to determine the MTD of twice-daily oral abemaciclib (150, 200 mg) plus pemetrexed, gemcitabine, or ramucirumab, followed by an expansion phase for each drug combination. Pemetrexed and gemcitabine were administered according to label. The abemaciclib plus ramucirumab study examined two dosing schedules.Results: The three study parts enrolled 86 patients; all received ≥1 dose of combination therapy. Across arms, the most common treatment-emergent adverse events were fatigue, diarrhea, neutropenia, decreased appetite, and nausea. The trial did not identify an abemaciclib MTD for the combination with pemetrexed or gemcitabine but did so for the combination of abemaciclib with days 1 and 8 ramucirumab (8 mg/kg). Plasma sample analysis showed that abemaciclib did not influence the pharmacokinetics of the combination agents and the combination agents did not affect abemaciclib exposure. The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab. Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.Conclusions: Abemaciclib demonstrated an acceptable safety profile when dosed on a continuous twice-daily schedule in combination with pemetrexed, gemcitabine, or ramucirumab. Abemaciclib exposures remained consistent with those observed in single-agent studies. Clin Cancer Res; 24(22); 5543-51. ©2018 AACR.

Published
2018

13. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Abidi, Maheen, Acoba, Jared D., Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H., Azad, Nilo, Bar, Michael H., Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H., Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W., Busser, Fiona, Cabal, Angelo, Caimi, Paolo, Carducci, Theresa, Casulo, Carla, Chen, James L., Clement, Jessica M, Chism, David, Cook, Erin, Curran, Catherine, Daher, Ahmad, Dailey, Mark, Dahiya, Saurabh, Deeken, John, Demetri, George D., DiLullo, Sandy, Duma, Narjust, Elias, Rawad, Faller, Bryan, Fecher, Leslie A., Feldman, Lawrence E., Friese, Christopher R., Fu, Paul, Fu, Julie, Futreal, Andy, Gainor, Justin, Garcia, Jorge, Gill, David M., Gillaspie, Erin A., Giordano, Antonio, Glace, (Mary) Grace, Grothey, Axel, Gulati, Shuchi, Gurley, Michael, Halmos, Balazs, Herbst, Roy, Hershman, Dawn, Hoskins, Kent, Jain, Rohit K., Jabbour, Salma, Jha, Alokkumar, Johnson, Douglas B., Joshi, Monika, Kelleher, Kaitlin, Kharofa, Jordan, Khan, Hina, Knoble, Jeanna, Koshkin, Vadim S., Kulkarni, Amit A., Lammers, Philip E., Leighton, John C., Jr, Lewis, Mark A., Li, Xuanyi, Li, Ang, Lo, K.M. Steve, Loaiza-Bonilla, Arturo, LoRusso, Patricia, Low, Clarke A., Lustberg, Maryam B., Mahadevan, Daruka, Mansoor, Abdul-Hai, Marcum, Michelle, Markham, Merry Jennifer, Handy Marshall, Catherine, Mashru, Sandeep H., Matar, Sara, McNair, Christopher, McWeeney, Shannon, Mehnert, Janice M., Menendez, Alvaro, Menon, Harry, Messmer, Marcus, Monahan, Ryan, Mushtaq, Sarah, Nagaraj, Gayathri, Nagle, Sarah, Naidoo, Jarushka, Nakayama, John M., Narayan, Vikram, Nelson, Heather H., Nemecek, Eneida R., Nguyen, Ryan, Nuzzo, Pier Vitale, Oberstein, Paul E., Olszewski, Adam J., Owenby, Susie, Pasquinelli, Mary M., Philip, John, Prabhakaran, Sabitha, Puc, Matthew, Ramirez, Amelie, Rathmann, Joerg, Revankar, Sanjay G., Rho, Young Soo, Rhodes, Terence D., Rice, Robert L., Riely, Gregory J., Riess, Jonathan, Rink, Cameron, Robilotti, Elizabeth V., Rosenstein, Lori, Routy, Bertrand, Rovito, Marc A., Saif, M. Wasif, Sanyal, Amit, Schapira, Lidia, Schwartz, Candice, Serrano, Oscar, Shah, Mansi, Shah, Chintan, Shaw, Grace, Shergill, Ardaman, Shouse, Geoffrey, Soares, Heloisa P., Solorzano, Carmen C., Srivastava, Pramod K., Stauffer, Karen, Stover, Daniel G., Stratton, Jamie, Stratton, Catherine, Subbiah, Vivek, Tamimi, Rulla, Tannir, Nizar M., Topaloglu, Umit, Van Allen, Eli, Van Loon, Susan, Vega-Luna, Karen, Venepalli, Neeta, Verma, Amit K., Vikas, Praveen, Wall, Sarah, Weinstein, Paul L., Weiss, Matthias, Wise-Draper, Trisha, Wood, William A., Xu, Wenxin (Vincent), Yackzan, Susan, Zacks, Rosemary, Zhang, Tian, Zimmer, Andrea J., West, Jack, Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Jr, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, and Warner, Jeremy L

Published
2020
Full Text
View/download PDF

16. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition

Author

Barzi, Afsaneh, primary, Weipert, Caroline M., additional, Espenschied, Carin R., additional, Raymond, Victoria M., additional, Wang-Gillam, Andrea, additional, Nezami, Mohammad Amin, additional, Gordon, Eva J., additional, Mahadevan, Daruka, additional, and Mody, Kabir, additional

Published
2024
Full Text
View/download PDF

20. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages

Author

Hung, Chia-Nung, primary, Chen, Meizhen, additional, DeArmond, Daniel T., additional, Chiu, Cheryl H.-L., additional, Limboy, Catherine A., additional, Tan, Xi, additional, Kusi, Meena, additional, Chou, Chih-Wei, additional, Lin, Li-Ling, additional, Zhang, Zhao, additional, Wang, Chiou-Miin, additional, Chen, Chun-Liang, additional, Mitsuya, Kohzoh, additional, Osmulski, Pawel A., additional, Gaczynska, Maria E., additional, Kirma, Nameer B., additional, Vadlamudi, Ratna K., additional, Gibbons, Don L., additional, Warner, Steve, additional, Brenner, Andrew J., additional, Mahadevan, Daruka, additional, Michalek, Joel E., additional, Huang, Tim H.-M., additional, and Taverna, Josephine A., additional

Published
2023
Full Text
View/download PDF

27. Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Author

Fong, Lawrence, primary, Hotson, Andrew, primary, Powderly, John D., primary, Sznol, Mario, primary, Heist, Rebecca S., primary, Choueiri, Toni K., primary, George, Saby, primary, Hughes, Brett G.M., primary, Hellmann, Matthew D., primary, Shepard, Dale R., primary, Rini, Brian I., primary, Kummar, Shivaani, primary, Weise, Amy M., primary, Riese, Matthew J., primary, Markman, Ben, primary, Emens, Leisha A., primary, Mahadevan, Daruka, primary, Luke, Jason J., primary, Laport, Ginna, primary, Brody, Joshua D., primary, Hernandez-Aya, Leonel, primary, Bonomi, Philip, primary, Goldman, Jonathan W., primary, Berim, Lyudmyla, primary, Renouf, Daniel J., primary, Goodwin, Rachel A., primary, Munneke, Brian, primary, Ho, Po Y., primary, Hsieh, Jessica, primary, McCaffery, Ian, primary, Kwei, Long, primary, Willingham, Stephen B., primary, and Miller, Richard A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Author

Fong, Lawrence, primary, Hotson, Andrew, primary, Powderly, John D., primary, Sznol, Mario, primary, Heist, Rebecca S., primary, Choueiri, Toni K., primary, George, Saby, primary, Hughes, Brett G.M., primary, Hellmann, Matthew D., primary, Shepard, Dale R., primary, Rini, Brian I., primary, Kummar, Shivaani, primary, Weise, Amy M., primary, Riese, Matthew J., primary, Markman, Ben, primary, Emens, Leisha A., primary, Mahadevan, Daruka, primary, Luke, Jason J., primary, Laport, Ginna, primary, Brody, Joshua D., primary, Hernandez-Aya, Leonel, primary, Bonomi, Philip, primary, Goldman, Jonathan W., primary, Berim, Lyudmyla, primary, Renouf, Daniel J., primary, Goodwin, Rachel A., primary, Munneke, Brian, primary, Ho, Po Y., primary, Hsieh, Jessica, primary, McCaffery, Ian, primary, Kwei, Long, primary, Willingham, Stephen B., primary, and Miller, Richard A., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Author

Babiker, Hani, primary, Borazanci, Erkut, primary, Subbiah, Vivek, primary, Agarwala, Sanjiv, primary, Algazi, Alain, primary, Schachter, Jacob, primary, Lotem, Michael, primary, Maurice-Dror, Corinne, primary, Hendler, Daniel, primary, Rahimian, Shah, primary, Minderman, Hans, primary, Haymaker, Cara, primary, Mahadevan, Daruka, primary, Bernatchez, Chantale, primary, Murthy, Ravi, primary, Hultsch, Rolf, primary, Kaplan, Nadia, primary, Woodhead, Gregory, primary, Hennemeyer, Charles, primary, Chunduru, Srinivas, primary, Anderson, Peter M., primary, Diab, Adi, primary, and Puzanov, Igor, primary

Published
2023
Full Text
View/download PDF

30. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)

Author

Fakih, Marwan, primary, Harb, Wael, additional, Mahadevan, Daruka, additional, Babiker, Hani, additional, Berlin, Jordan, additional, Lillie, Tom, additional, Krige, David, additional, Carter, Jo, additional, Cox, Chris, additional, Patel, Minesh, additional, Parfitt, Lola, additional, Powell, Mark, additional, and Rosen, Lee, additional

Published
2023
Full Text
View/download PDF

31. Appendix figures from Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Author

Kim, Edward S., primary, Kelly, Karen, primary, Paz-Ares, Luis G., primary, Garrido, Pilar, primary, Jalal, Shadia, primary, Mahadevan, Daruka, primary, Gutierrez, Martin, primary, Provencio, Mariano, primary, Schaefer, Eric, primary, Shaheen, Monte, primary, Johnston, Erica L., primary, Turner, P. Kellie, primary, Kambhampati, Siva Rama Prasad, primary, Beckmann, Richard, primary, Hossain, Anwar, primary, John, William J., primary, and Goldman, Jonathan W., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma

Author

Zullo, Kelly M., primary, Guo, Yige, primary, Cooke, Laurence, primary, Jirau-Serrano, Xavier, primary, Mangone, Michael, primary, Scotto, Luigi, primary, Amengual, Jennifer E., primary, Mao, Yinghui, primary, Nandakumar, Renu, primary, Cremers, Serge, primary, Duong, Jimmy, primary, Mahadevan, Daruka, primary, and O'Connor, Owen A., primary

Published
2023
Full Text
View/download PDF

33. Appendix text from Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Author

Kim, Edward S., primary, Kelly, Karen, primary, Paz-Ares, Luis G., primary, Garrido, Pilar, primary, Jalal, Shadia, primary, Mahadevan, Daruka, primary, Gutierrez, Martin, primary, Provencio, Mariano, primary, Schaefer, Eric, primary, Shaheen, Monte, primary, Johnston, Erica L., primary, Turner, P. Kellie, primary, Kambhampati, Siva Rama Prasad, primary, Beckmann, Richard, primary, Hossain, Anwar, primary, John, William J., primary, and Goldman, Jonathan W., primary

Published
2023
Full Text
View/download PDF

34. Figure S2 from Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Author

Kelly, Kevin R., primary, Friedberg, Jonathan W., primary, Park, Steven I., primary, McDonagh, Kevin, primary, Hayslip, John, primary, Persky, Daniel, primary, Ruan, Jia, primary, Puvvada, Soham, primary, Rosen, Peter, primary, Iyer, Swaminathan Padmanabhan, primary, Stefanovic, Alexandra, primary, Bernstein, Steven H., primary, Weitman, Steven, primary, Karnad, Anand, primary, Monohan, Gregory, primary, VanderWalde, Ari, primary, Mena, Raul, primary, Schmelz, Monika, primary, Spier, Catherine, primary, Groshen, Susan, primary, Venkatakrishnan, Karthik, primary, Zhou, Xiaofei, primary, Sheldon-Waniga, Emily, primary, Leonard, E. Jane, primary, and Mahadevan, Daruka, primary

Published
2023
Full Text
View/download PDF

35. Video 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma

Author

Zullo, Kelly M., primary, Guo, Yige, primary, Cooke, Laurence, primary, Jirau-Serrano, Xavier, primary, Mangone, Michael, primary, Scotto, Luigi, primary, Amengual, Jennifer E., primary, Mao, Yinghui, primary, Nandakumar, Renu, primary, Cremers, Serge, primary, Duong, Jimmy, primary, Mahadevan, Daruka, primary, and O'Connor, Owen A., primary

Published
2023
Full Text
View/download PDF

36. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

Author

El-Khoueiry, Anthony B., primary, Fakih, Marwan, additional, Gordon, Michael S., additional, Tsimberidou, Apostolia Maria, additional, Bullock, Andrea J., additional, Wilky, Breelyn A., additional, Trent, Jonathan C., additional, Margolin, Kim Allyson, additional, Mahadevan, Daruka, additional, Balmanoukian, Ani Sarkis, additional, Sanborn, Rachel E., additional, Schwartz, Gary K., additional, Bockorny, Bruno, additional, Moser, Justin C, additional, Grossman, Joseph Elan, additional, Ortuzar Feliu, Waldo Ignacio, additional, Rosenthal, Katherine, additional, O'Day, Steven, additional, Lenz, Heinz-Josef, additional, and Schlechter, Benjamin L., additional

Published
2023
Full Text
View/download PDF

38. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma

Author

Sardar, Muhammad, primary, Recio-Boiles, Alejandro, additional, Mody, Kabir, additional, Karime, Christian, additional, Chandana, Sreenivasa R, additional, Mahadevan, Daruka, additional, Starr, Jason, additional, Jones, Jeremy, additional, Borad, Mitesh, additional, and Babiker, Hani, additional

Published
2022
Full Text
View/download PDF

39. A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Author

Samaniego, Felipe, primary, Sadiq, Ahad A., additional, Mahadevan, Daruka, additional, Koontz, Michael Z., additional, Villasboas, Jose C., additional, Burke, John M., additional, Reid, Erin G, additional, Cherry, Mohamad, additional, Melear, Jason, additional, Priego, Victor, additional, Cobb, Patrick, additional, Cull, Elizabeth H., additional, Conkling, Paul, additional, Cosgrove, David, additional, Roeker, Lindsey E., additional, Nguyen Haney, Donna, additional, Hu, Jia, additional, Sinha, Ranjeet Kumar, additional, Rice, William G, additional, and Bejar, Rafael, additional

Published
2022
Full Text
View/download PDF

40. 778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors

Author

Wilky, Breelyn, primary, El-Khoueiry, Anthony, additional, Bullock, Andrea, additional, Tsimberidou, Apostolia, additional, Mahadevan, Daruka, additional, Margolin, Kim, additional, Trent, Jonathan, additional, Bockorny, Bruno, additional, Moser, Justin, additional, Hosein, Peter, additional, Fakih, Marwan, additional, Schlecter, Benjamin, additional, Thomas, Jacob, additional, Balmanoukian, Ani, additional, Sanborn, Rachel, additional, Abou-Alfa, Ghassan, additional, Schwartz, Gary, additional, Hanna, Diana, additional, Feliu, Waldo Ortuzar, additional, Grossman, Joseph, additional, Rosenthal, Katherine, additional, Godwin, James, additional, Patel, Jaymin, additional, Bullock, Bonnie, additional, Stebbing, Justin, additional, Rawal, Bhupendra, additional, Cole, Hunter, additional, Delepine, Chloe, additional, Chow, Jacky, additional, Walker, Ross, additional, MacDermaid, Chris, additional, Chand, Dhan, additional, Gordon, Michael, additional, Lenz, Heinz-Josef, additional, and O’Day, Steven, additional

Published
2022
Full Text
View/download PDF

44. Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

Author

Sharman, Jeff P., Farber, Charles M., Mahadevan, Daruka, Schreeder, Marshall T., Brooks, Heather D., Kolibaba, Kathryn S., Fanning, Suzanne, Klein, Leonard, Greenwald, Daniel R., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., and Burke, John M.

Published
2017
Full Text
View/download PDF

45. Abstract CT128: A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Author

Spigel, David R., primary, Whitehead, Zachary, additional, Kim, Young, additional, Szado, Tania, additional, McDonald, Anne, additional, Darbonne, Walter C., additional, Levy, Jonathan, additional, Borden, Eucharia, additional, Mahadevan, Daruka, additional, and VanderWalde, Ari, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results